阿扎司琼和格拉司琼在白血病化疗后的疗效对比

Comparison of Efficacy of Azasetron and Granisetron After Chemotherapy for Leukemia

目的本次研究以急性髓系白血病(acute myelogenous leukemia,AML)患者为研究对象,分析在接受化疗方案治疗的过程中重点对比阿扎司琼、格拉司琼在其中的疗效,旨在为临床用药提供参考。方法于2018年8月—2020年11月收治53例急性髓系白血病患者为研究对象,随机分为2组,A组预防性使用阿扎司琼,B组预防性使用格拉司琼,记录两组疗效及不良反应。结果B组疗效高于A组,但两组有效率比较差异无统计学意义(P>0.05)。两组副作用差异无统计学意义(P>0.05)。结论阿扎司琼与格拉司琼对预防急性髓系白血病联合化疗所致的恶心呕吐作用相似,不良反应略有不同。

Objectiv To investigate the efficacy of azasetron versus granisetron in patients with acute myelogenous leukemia(AML)after chemotherapy.Methods From August 2018 to November 2020,53 patients with acute myeloid leukemia were randomly divided into two groups.Group A was treated with azasetron and group B was treated with granisetron.Results The curative effect of group B was higher than that of group A,but there was no significant difference between the two groups(P>0.05).There was no significant difference in s ide effects between the two groups(P>0.05).Conclusion Azasetron and granisetron have similar effect on preventing nausea and vomiting caused by acute myeloid leukemia combined with chemotherapy,but their adverse reactions are slightly different.